Source:http://linkedlifedata.com/resource/pubmed/id/19109560
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
2009-2-17
|
pubmed:databankReference | |
pubmed:abstractText |
A noninferiority study was performed comparing low-dose and standard-dose prophylactic platelet transfusions. A double-blind randomized controlled trial (RCT) was performed in 6 sites in 3 countries. Thrombocytopenic adults requiring prophylactic platelet transfusion were randomly allocated to standard-dose (300-600 x 10(9) platelets/product) or low-dose (150- < 300 x 10(9) platelets/product) platelets. The primary outcome (World Health Organization [WHO] bleeding > or = grade 2) was assessed daily through clinical examination, patient interview, and chart review. A WHO grade was assigned through adjudication. The Data Safety Monitoring Board stopped the study because the difference in the grade 4 bleeding reached the prespecified threshold of 5%. At this time, 129 patients had been randomized and 119 patients were included in the analysis (58 low dose; 61 standard dose). Three patients in the low-dose arm (5.2%) had grade 4 bleeds compared with none in the standard-dose arm. WHO bleeding grade 2 or higher was 49.2% (30/61) in the standard-dose arm and 51.7% (30/58) in the low-dose group (relative risk [RR], 1.052; 95% confidence interval [CI], 0.737-1.502). A higher rate of grade 4 bleeding in patients receiving low-dose prophylactic platelet transfusions resulted in this RCT being stopped. Whether this finding was due to chance or represents a real difference requires further investigation. These clinical studies are registered on (http://www.clinicaltrials.gov) as NCT00420914.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1528-0020
|
pubmed:author |
pubmed-author:AuBuchonJames PJP,
pubmed-author:BartyRebecca LRL,
pubmed-author:BrandweinJoseph MJM,
pubmed-author:CookRichard JRJ,
pubmed-author:HeddleNancy MNM,
pubmed-author:HervigTorT,
pubmed-author:KlapperEllenE,
pubmed-author:KouroukisC TomCT,
pubmed-author:LeeKer-AiKA,
pubmed-author:SToP Study Investigators of the BEST Collaborative,
pubmed-author:SzczepiorkowskiZbigniew MZM,
pubmed-author:TinmouthAlanA
|
pubmed:issnType |
Electronic
|
pubmed:day |
12
|
pubmed:volume |
113
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1564-73
|
pubmed:meshHeading |
pubmed-meshheading:19109560-Adult,
pubmed-meshheading:19109560-Aged,
pubmed-meshheading:19109560-Antineoplastic Agents,
pubmed-meshheading:19109560-Female,
pubmed-meshheading:19109560-Hemorrhage,
pubmed-meshheading:19109560-Humans,
pubmed-meshheading:19109560-Leukemia, Myeloid, Acute,
pubmed-meshheading:19109560-Male,
pubmed-meshheading:19109560-Middle Aged,
pubmed-meshheading:19109560-Platelet Count,
pubmed-meshheading:19109560-Platelet Transfusion,
pubmed-meshheading:19109560-Severity of Illness Index,
pubmed-meshheading:19109560-Thrombocytopenia,
pubmed-meshheading:19109560-World Health Organization
|
pubmed:year |
2009
|
pubmed:articleTitle |
A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia.
|
pubmed:affiliation |
Department of Medicine, McMaster University, Hamilton, ON, Canada. heddlen@mcmaster.ca
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Case Reports,
Research Support, Non-U.S. Gov't,
Multicenter Study
|